243 related articles for article (PubMed ID: 33349623)
1. Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation.
Hernandez-Valladares M; Aasebø E; Berven F; Selheim F; Bruserud Ø
Aging (Albany NY); 2020 Dec; 12(24):24734-24777. PubMed ID: 33349623
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
[TBL] [Abstract][Full Text] [Related]
3. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
[TBL] [Abstract][Full Text] [Related]
4. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.
Bruserud Ø; Reikvam H; Fredly H; Skavland J; Hagen KM; van Hoang TT; Brenner AK; Kadi A; Astori A; Gjertsen BT; Pendino F
Oncotarget; 2015 Feb; 6(5):2794-811. PubMed ID: 25605239
[TBL] [Abstract][Full Text] [Related]
5. Aldehyde Dehydrogenase Genes as Prospective Actionable Targets in Acute Myeloid Leukemia.
Dancik GM; Varisli L; Tolan V; Vlahopoulos S
Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761947
[TBL] [Abstract][Full Text] [Related]
6. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML.
Heuser M; Argiropoulos B; Kuchenbauer F; Yung E; Piper J; Fung S; Schlenk RF; Dohner K; Hinrichsen T; Rudolph C; Schambach A; Baum C; Schlegelberger B; Dohner H; Ganser A; Humphries RK
Blood; 2007 Sep; 110(5):1639-47. PubMed ID: 17494859
[TBL] [Abstract][Full Text] [Related]
7. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.
Nepstad I; Hatfield KJ; Aasebø E; Hernandez-Valladares M; Brenner AK; Bartaula-Brevik S; Berven F; Selheim F; Skavland J; Gjertsen BT; Reikvam H; Bruserud Ø
Expert Opin Ther Targets; 2018 Jul; 22(7):639-653. PubMed ID: 29889583
[TBL] [Abstract][Full Text] [Related]
8. CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.
Brenner AK; Reikvam H; Rye KP; Hagen KM; Lavecchia A; Bruserud Ø
Molecules; 2017 Mar; 22(3):. PubMed ID: 28287460
[TBL] [Abstract][Full Text] [Related]
9. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
10. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
[TBL] [Abstract][Full Text] [Related]
12. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
Reikvam H; Hovland R; Forthun RB; Erdal S; Gjertsen BT; Fredly H; Bruserud Ø
BMC Cancer; 2017 Sep; 17(1):630. PubMed ID: 28877686
[TBL] [Abstract][Full Text] [Related]
13. Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.
Hömme C; Krug U; Tidow N; Schulte B; Kühler G; Serve H; Bürger H; Berdel WE; Dugas M; Heinecke A; Büchner T; Koschmieder S; Müller-Tidow C
Oncol Rep; 2010 Jul; 24(1):47-56. PubMed ID: 20514443
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional Silencing of
Yang Z; Wu XS; Wei Y; Polyanskaya SA; Iyer SV; Jung M; Lach FP; Adelman ER; Klingbeil O; Milazzo JP; Kramer M; Demerdash OE; Chang K; Goodwin S; Hodges E; McCombie WR; Figueroa ME; Smogorzewska A; Vakoc CR
Cancer Discov; 2021 Sep; 11(9):2300-2315. PubMed ID: 33893150
[TBL] [Abstract][Full Text] [Related]
16. Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients.
Li X; Xu L; Sheng X; Cai J; Liu J; Yin T; Xiao F; Chen F; Zhong H
Exp Hematol; 2018 Dec; 68():66-79.e3. PubMed ID: 30208330
[TBL] [Abstract][Full Text] [Related]
17. Insights into cell ontogeny, age, and acute myeloid leukemia.
Chaudhury SS; Morison JK; Gibson BE; Keeshan K
Exp Hematol; 2015 Sep; 43(9):745-55. PubMed ID: 26051919
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
19. Characterization of purine-rich element binding protein B as a novel biomarker in acute myelogenous leukemia prognostication.
Kelm RJ; Lamba GS; Levis JE; Holmes CE
J Cell Biochem; 2018 Feb; 119(2):2073-2083. PubMed ID: 28834593
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
